Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 15, 2009

Genentech Taps Graffinity’s Fragment-Based Drug Discovery Technology

  • Genentech has obtained access to Graffinity Pharmaceuticals’ fragment-based drug discovery technology. Graffinity will receive technology access fees and optional payments for follow-up chemistry for the generation of novel, small molecule hits against a number of drug targets. 


Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »